By Sneha S K and Maggie Fick (Reuters) -Bristol Myers Squibb said on Monday it plans to launch its schizophrenia drug, ...
With a Sept. 29 deadline looming for pharmaceutical companies to adhere to President Donald Trump’s most favored nation drug ...
Karuna Therapeutics and Bristol Myers Squibb are winners of the 2025 Gizmodo Science Fair for their research and development ...
Schizophrenia care is shifting. In this article, Dr. Stella Sarraf, founder and CEO of Spinogenix, and Dr. David Walling, ...
The consequences of President Trump's actions on drug pricing continue to play out, with Bristol Myers Squibb insisting it ...
US pharma major Bristol Myers Squibb revealed plans to launch Cobenfy (xanomeline and trospium chloride) in the UK in 2026.
The company, which is developing a competitor to Cobenfy, aims to become one of rare biotechs to price a large IPO of late.
Bristol Myers Squibb plans to launch Cobenfy (xanomeline and trospium chloride), in the UK in 2026. The UK would be the first country in Europe to make this medicine available for adults living with ...
Bristol-Myers Squibb is the latest drugmaker to raise drug prices abroad to align with President Donald Trump's "most favored nation" drug pricing ...
MedPage Today on MSN
Soda-Major Depression Link; FDA Rejects Rexulti for PTSD; Cobenfy Neutropenia Case
The FDA rejected brexpiprazole (Rexulti) in combination with sertraline for post-traumatic stress disorder (PTSD), said ...
Cobenfy demonstrated statistically significant improvements in schizophrenia symptoms. Bristol Myers Squibb acquired Karuna Therapeutics' treatment in a $14 billion deal, marking a significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback